Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 22, 2018
Pharmacy Choice - News - U.S. Pharmaceutical Industry - April 22, 2018

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/22/18 - Global Probiotic Dietary Supplement Market Growth Opportunities, Driving Factors by Manufacturers, Regions, Type & Application, Forecast to 2023
Market Study Report Add New Global Probiotic Dietary Supplement Market by Manufacturers, Countries, Type and Application, forecast to 2023 to its research database presenting an informative study covering the market with detailed analysis. The report...
4/22/18 - Health and Human Services Department (HHS); Food and Drug Administration (FDA) (F.R. Page 11759) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Arthritis Advisory Committee to discuss new drug application 207924, for baricitinib tablets, submitted by Eli Lilly and Company, for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate resp
4/22/18 - Livingston mom battles breast cancer with experimental treatments to help other patients [Detroit Free Press]
Kimberlie Newton can't wallow in the agony of regret. She has enrolled in a clinical trial at the Barbara Ann Karmanos Cancer Institute, hoping that by trying experimental drugs and therapies that have yet to be approved by the U.S. Food and Drug Administration, she might find something new that will give her more time with her husband and son.
4/22/18 - New hope in fight against ovarian cancer; Early trial shows targeted therapy looks promising
Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope. One study found that a new targeted "immunotherapy" to treat ovarian cancer that has come back looked promising in a small, early trial. Eva Chalas, director of the Center for Cancer Care at NYU Winthrop Hospital in Mi
4/22/18 - Patent Issued for Uses of Cistanche Tubulosa Extract and Isoacteoside in Protecting Muscle (USPTO 9931367)
By a News Reporter-Staff News Editor at Heart Disease Weekly According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Wang, Chao-Jih; Yeh, Ai-Ling, filed on January 11, 2017, was published online on April 3, 2018. The assignee for this patent, patent number 9931367, is Sinphar Tian-Li Pha
4/22/18 - Scott Meacham: Great Oklahoma stories of entrepreneurship
If you are a regular reader of these columns, and I hope you are, you can tell that I like history. Take Novazyme Pharmaceuticals, founded by William Canfield, M.D., Ph.D., formerly a scientist at the University of Oklahoma Health Sciences Center and taken through a much-heralded exit by CEO John Crowley. Crowley, an experienced drug industry execu
4/21/18 - "Beam Shaping Assembly for Neutron Capture Therapy" in Patent Application Approval Process (USPTO 20180085604)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors Liu, Yuan-Hao; Lee, Pei-Yi, filed on November 29, 2017, was made available online on April 5, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. By virtue of specific grouping of boronated pharm
4/21/18 - 10xBio Raises $2.7M to Test Body Sculpting Drug in Clinical Trial [Syrian Arab News Agency]
John Dobak, a life sciences serial entrepreneur in San Diego, said a new startup hes leading has raised $2.66 million to advance a drug that is already approved to shrink varicose veins through early-stage clinical trials testing it in a new use fat reduction body sculpting. The biotech, 10 xBio, announced earlier this month that the FDA had approv
4/21/18 - Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease [All Iraq News Agency (AIN)]
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeonas gene therapy program ABO-202 for...
4/21/18 - An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR.)
GW Pharmaceuticals plc's cannabis-based drug for epilepsy, Epidiolex, won the unanimous backing of an advisory panel to the FDA on April 19, 2018. The FDA's final decision on Epidiolex is expected by June 27, 2018. If approved, Epidiolex would be the first-ever medicine derived from a marijuana plant to be greenlighted by the FDA.
4/21/18 - AZ`s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer [Tehran Times (Iran)]
AstraZeneca has announced that its epidermal growth factor receptor tyrosine kinase inhibitor Tagrisso has received approval from the FDA for the first-line treatment of metastatic non-small cell lung cancer in patients whose tumours have EGFR mutations, specifically exon 19 deletions or exon 21 L858R mutations, as detected by an FDA- approved test
4/21/18 - AZs Tagrisso approved for untreated lung cancer in US [Tehran Times (Iran)]
AstraZenecas Tagrisso looks set to gain further traction after the FDA approved it in first-line treatment for lung cancer patients with a certain mutation. Dr Suresh Ramalingam, principal investigator of the FLAURA trial, from Winship Cancer Institute of Emory University, Atlanta, said: The approval of osimertinib in the first-line setting represe
4/21/18 - Bellicum Pharmaceuticals Announces Closing of Public Offering [T-break Tech (Middle East)]
-Bellicum Pharmaceuticals, Inc. a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold...
4/21/18 - Bluebird Bio One Step Closer to First Approved Drug [Arab News (Saudi Arabia)]
Bluebird bio, headquartered in Cambridge, Massachusetts, announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia. The two studies are Northstar, which was recently completed, and HGB-205, which is still proceeding. These interim data demonstrate the potential of...
4/21/18 - Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
Bridge Medicines, launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine, in partnership with Takeda Pharmaceutical Company Ltd., Deerfield Management and Bay City Capital, is a groundbreaking initiative that extends the work of the independent, non-profit Tri-Institutional Therapeutics Discovery..
4/21/18 - Dr. Bob Harman, CEO of VetStem Biopharma, Speaks on Stem Cells at Second Annual International Regenerative Medicine Conference in Costa Rica [Sport360]
Bob Harman, founder and CEO of VetStem Biopharma, Inc., has been asked to speak at the second annual International Regenerative Medicine Conference which will take place on April 25-26, 2018 in Costa Rica. Dr. Harman has been a leader in the field of regenerative medicine for over a decade and has presented on the topic at both human and animal con
4/21/18 - Drugmakers compete to develop liver drugs [All Iraq News Agency (AIN)]
To widen live treatment options, Pharmicell, HLB Life Science, SillaJen, Samil Pharmaceutical, and Hanmi Pharmaceutical are accelerating researches on various drug candidates. Pharmicell, which has a stem cell treatment called Hearticellgram, is waiting to obtain conditional approval for Cellgram LC, a stem cell therapy for cirrhosis.
4/21/18 - Expanding Conditional Approvals in Animal Drug User Fee Act Is Bad for Public Health
U.S. PIRG delivered a letter signed by health professionals from across the country urging members of the House Energy and Commerce Committee not to expand conditional approvals when they consider the bill next week. Despite that threat, approximately 70% of the medically-important antibiotics sold in the U.S. each year go to food animals, and the
4/21/18 - Expanding Conditional Approvals in the Animal Drug User Fee Act Is Bad For Public Health
U.S. PIRG delivered a letter signed by health professionals from across the country urging members of the House Energy and Commerce Committee not to expand conditional approvals when they consider the bill next week. Despite that threat, approximately 70% of the medically-important antibiotics sold in the U.S. each year go to food animals, and the
4/21/18 - FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia [Sudan Tribune]
The U.S Food and Drug Administration has approved Crysvita, the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia, a rare, inherited form of rickets. XLH differs from other forms of rickets in that vitamin D therapy is not effective, stated Dr Julie Beitz, director of the Office of Drug Evaluation
4/21/18 - FDA Approves Osimertinib for Treatment of Non-Small Cell Lung Cancer [Tehran Times (Iran)]
Officials with the FDA have approved osimertinib for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor mutations, according to a press release. Osimertinib is already approved in the United States for the second-line treatment of patients with metastatic EGFRm NSCLC,..
4/21/18 - Grassley seeks information from HHS, FDA on unproven medical procedures touted as clinical trials [Syrian Arab News Agency]
Chuck Grassley of Iowa sent a letter to Department of Health and Human Services Secretary Alex Azar and Food and Drug Administration Commissioner Dr. A March 15, 2017 Washington Post report detailed three women in South Florida who participated in what they believed was a government-backed clinical trial to reverse the effects of macular degenerati
4/21/18 - Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO (fosnetupitant/ palonosetron) in the United States
-Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO in the United States. Lugano, Switzerland April 20, 2018- Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration has approved the intravenous formulation of AKYNZEO as an alternative
4/21/18 - Ionis to get $1 billion cash in expanded deal with Biogen [Arab Times (Kuwait)]
Carlsbads Ionis Pharmaceuticals will get $1 billion cash to help Biogen of Cambridge, Mass., develop neurological drugs, the companies announced Friday. The payment is the largest amount for a research collaboration in the history of Ionis, said Stanley T. Crooke. Ionis gets $375 million upfront.
4/21/18 - Ionis to get $1 billion cash in expanded deal with Biogen [The San Diego Union-Tribune]
April 20 Carlsbad's Ionis Pharmaceuticals will get $1 billion cash to help Biogen of Cambridge, Mass., develop neurological drugs, the companies announced Friday. The payment is the largest amount for a research collaboration in the history of Ionis, said Stanley T. Crooke. Ionis gets $375 million upfront.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415